Brief: BioCryst Pharmaceuticals Q3 EPS USD -0.07 Vs. IBES Estimate USD -0.06
04/11/2024 12:00
Nov 04 (Reuters) - BioCryst Pharmaceuticals Q3 product sales USD 117.085 million. * Q3 operating expenses USD 109.393 million * Q3 net income USD -14.033 million vs. IBES estimate USD -14.2 million * Q3 operating income USD 7.692 million vs. IBES estimate USD 8.18 million * Q3 pretax profit USD -13.447 million vs. IBES estimate USD -13 million
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026